Biomedica Management Corporation focuses on the development of therapeutic agents that address needs in coagulopathic conditions, hemostasis, resuscitation, and sepsis. The company provides general histology services (paraffin and frozen), immunohistochemistry services (general IHC, antibody testing/validation, and cross-reactivity studies), histopathology for preclinical toxicology studies, and resin/plastic sectioning for implantable medical devices and bone. It also offers GLP and non-GLP services, resin sectioning RNAse free protocols, special stains, immunohistochemistry in situ, hybridization antibody testing and protocol development, research and development on new methods, image processing, and pathological scoring and analysis. The Company's most clinically advanced product candidate ClotFoam is designed to improve hemostasis in patients undergoing a wide range of surgical and medical procedures.
